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After publication of our recent article [1] we noticed a
typographical error in the Results section. The sentence,
‘Celecoxib, at both licensed and any dose always produced
more endoscopic ulcers than NSAID’ should read,
‘Celecoxib, at both licensed and any dose always produced
fewer endoscopic ulcers than NSAID’. The relevant section of
our article with corrected text follows below:
Endoscopically detected ulcers
Seven trials were designed to detect the presence of
endoscopic ulcers of 3 mm or more, in which celecoxib was
compared with placebo and/or NSAID (additional file 4). Six
reported at 12 weeks, and one at 24 weeks. Five trials also
reported results according to the use of low dose aspirin of
325 mg or less daily. These results are shown in Table 8 and
Figure 4, analysed across all patients and according to
aspirin use. In no comparison was there any significant
difference between celecoxib and placebo. For both
celecoxib and NSAID there was the same 6% absolute
increase in endoscopic ulcers with aspirin use. Celecoxib, at
both licensed and any dose always produced fewer
endoscopic ulcers than NSAID. The NNTp was the same at
7-8 both with and without concomitant aspirin use.
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